Scarica l'app Stockscreener
84.27
0.73%
0.61
Dopo l'orario di chiusura:
83.79
-0.48
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$83.66
Aprire:
$83.36
Volume 24 ore:
3.02M
Relative Volume:
0.77
Capitalizzazione di mercato:
$48.90B
Reddito:
$5.88B
Utile/perdita netta:
$1.34B
Rapporto P/E:
35.88
EPS:
2.3489
Flusso di cassa netto:
$799.60M
1 W Prestazione:
-0.09%
1M Prestazione:
-2.97%
6M Prestazione:
+5.34%
1 anno Prestazione:
+22.15%
Intervallo 1D:
$83.25
$84.56
Intervallo di 1 settimana:
$82.82
$86.19
Portata 52W:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.27 | 48.55B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
108.77 | 186.79B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.55 | 137.19B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.98 | 135.78B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.67 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Judge: Edwards/Jenavalve would create “total monopoly” - Global Competition Review
Sector Gamma AS Acquires 30,980 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 25,276 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Profit Review: Will Edwards Lifesciences Corporation outperform its industry peersMarket Rally & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Heart Valve Deal Was Blocked Over Innovation Concerns - Law360
Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance - MarketBeat
What to expect from Edwards Lifesciences' Q4 2025 earnings report - MSN
Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Allstate Corp Buys Shares of 21,090 Edwards Lifesciences Corporation $EW - MarketBeat
VIX Spike: Can GBFH sustain earnings growthJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Action: Is Edwards Lifesciences Corporation showing insider buyingQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Edwards Lifesciences (EW) Receives New Analyst Target Price from Piper Sandler | EW Stock News - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $110 on TAVR growth - Investing.com Canada
Edwards Lifesciences Corp. Still Trying To Regain Footing - AOL.com
Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential? - Yahoo Finance
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) S&P 500 Index Medical Device Presence - Kalkine Media
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update - MarketBeat
Edwards’ Heart Valve Clips Targeted by Cardiovalve Patent Suit - Bloomberg Law News
Market Review: Whats the outlook for Edwards Lifesciences Corporations sectorPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy - Benzinga
Edwards Lifesciences (EW) Valuation Check As Recent Share Momentum Meets Premium P/E Pricing - Yahoo Finance
Risk Report: Does Edwards Lifesciences Corporation align with a passive investing strategy2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
JPM26: Edwards Lifesciences targets 10% growth in 2026 - Yahoo Finance
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report - Yahoo Finance
Nordea Investment Management AB Sells 110,464 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Spire Wealth Management Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Revises Edwards Lifesciences (EW) Price Target and Maintains Neutral Rating | EW Stock News - GuruFocus
Barclays Raises Price Target for Edwards Lifesciences (EW) to $1 - GuruFocus
FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - ocbj.com
Edwards scraps Jenavalve buy in face of FTC objections - BioWorld MedTech
Edwards Lifesciences (EW) Faces Legal Setback in Acquisition Pla - GuruFocus
Edwards Lifesciences Corp Acquisition Blocked by FTC - TradingView — Track All Markets
Hardman Johnston Global Advisors LLC Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Drops Bid to Acquire JenaValve Technology - marketscreener.com
Oregon Public Employees Retirement Fund Increases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards won’t acquire JenaValve after FTC blocks deal - MassDevice
Parnassus Investments LLC Takes $36.93 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Explores Personalized Blood Pressure Targets in New Study - MSN
US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Reuters
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Bitget
Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $87,328.30 in Stock - MarketBeat
Edwards Lifesciences (EW) Updates Earnings Guidance for 2023 - GuruFocus
Edwards Lifesciences (EW) Acquisition Blocked by Court - GuruFocus
Edwards says co will not acquire Jenavalve - marketscreener.com
US court blocks heart valve deal; Edwards boosts outlook, backs therapy - Stock Titan
Court sides with FTC to put Edwards Lifesciences’ JenaValve acquisition on hold - MassDevice
Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares - Stock Titan
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.63%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):